Praxis Precision Medicines Reports POWER1 Study Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 01 2026
0mins
Praxis Precision Medicines Inc. shares fell 8.42% as the stock hit a 5-day low amid disappointing results from the POWER1 study of vormatrigine.
The POWER1 study did not meet its primary endpoint, but a 50% responder rate was noted in the higher dose group, indicating some efficacy. Additionally, approximately 90% of patients transitioned to the open-label extension study, suggesting good tolerability with adverse event-related discontinuations below 10%. However, the company announced a pause in enrollment for the POWER2 study to reassess the program, reflecting a cautious approach to future clinical development.
The market reaction has been negative, with shares dropping significantly following the study results. Despite the setbacks, there remains optimism regarding the safety profile of vormatrigine and the potential for future drug launches, which may provide new growth opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRAX
Wall Street analysts forecast PRAX stock price to rise
15 Analyst Rating
14 Buy
0 Hold
1 Sell
Strong Buy
Current: 270.010
Low
95.00
Averages
456.71
High
843.00
Current: 270.010
Low
95.00
Averages
456.71
High
843.00
About PRAX
Praxis Precision Medicines, Inc. is an integrated, central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company's product candidates include Ulixacaltamide, Vormatrigine, Relutrigine, PRAX-080, Elsunersen, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RBC Capital Markets Initiates Praxis Precision with Outperform Rating
- Positive Market Outlook: RBC Capital Markets has initiated coverage on Praxis Precision Markets with an outperform rating, citing a recent pullback as a good entry point, and they expect a transformative next six months with a price target of $449, representing a 66% upside from the June 17 close.
- Significant Sales Potential: Analyst Leonid Timashev highlighted that ulixacaltamide has a sales potential exceeding $4.3 billion for essential tremor, acknowledging regulatory risks but noting strong physician willingness to prescribe, indicating a large unmet need in the market.
- Long-term Revenue Prospects: Timashev also mentioned that Praxis could achieve over $7.8 billion in revenue by 2035, which is attractive to investors and suggests strong growth potential in future market competition.
- New Drug Development Opportunities: For genetically driven epilepsy, Timashev sees a high probability of success for relutrigine, while elsunersen could contribute an additional $200 million for the most severe patients, although feedback indicates not all families would opt for this antisense oligonucleotide treatment.
See More
Latest Wall Street Rating Updates
- Apple Rating Reaffirmed: Bank of America reiterates Apple as a buy, believing that price increases are already reflected in the stock, anticipating that rising memory costs will force Apple to raise prices, impacting future earnings performance.
- Nice Upgrade: DA Davidson upgrades Nice from neutral to buy, maintaining a $110 price target, arguing that concerns about AI disruption are overblown, suggesting a more optimistic outlook that could boost the company's stock price.
- Immix Biopharma Initiation: Bank of America initiates coverage of Immix Biopharma with a buy rating and a $27 price target, citing the company's differentiated product offerings as a significant growth driver.
- Salesforce Upgrade: Monness Crespi Hardt upgrades Salesforce from neutral to buy with a $200 price target, based on its depressed valuation, strong cash flow generation, and support for customer transformation, which are expected to drive stock price increases.
See More
Wedbush Lowers Praxis Price Target to $162 After POWER1 Miss
- POWER1 Study Failure: Praxis Precision Medicines Inc.'s POWER1 study failed to meet its primary endpoint, prompting Wedbush to lower its 12-month price target from $355 to $162 while maintaining an Underperform rating, reflecting concerns over clinical development uncertainty.
- Need for Dose Adjustment: Although a more pronounced seizure reduction was observed at the 30mg dose, it still did not meet the prespecified endpoint, leading Praxis to pause enrollment in the POWER2 study to reassess potential modifications, indicating a cautious approach to future research directions.
- Positive Outlook for IDEAYA: Wedbush reaffirmed its Outperform rating on IDEAYA Biosciences with a price target of $58, based on positive results from the OptimUM-02 study, which demonstrated significant improvement in progression-free survival with Darovasertib plus Crizotinib compared to the control group.
- Strategic Deal for Edgewise: Edgewise Therapeutics reached a $1.55 billion agreement with Servier to sell all rights to Sevasemten, providing non-dilutive capital to strengthen its financial position and support a strategic focus on cardiac programs.
See More
US Stocks Close at All-Time Highs as AI Investments Surge
- Strong Market Performance: The S&P 500 rose by 0.13%, the Dow Jones by 0.45%, and the Nasdaq 100 by 0.48%, with all three indices reaching new all-time highs, reflecting strong investor confidence in tech stocks amid a surge in AI investments.
- Marvell Technology Soars: Marvell Technology's stock surged over 32% after Nvidia CEO Jensen Huang predicted the company would be the next to achieve a $1 trillion valuation, significantly boosting investor confidence in its future growth prospects.
- Hewlett Packard Enterprise's Strong Earnings: Hewlett Packard Enterprise's stock jumped more than 19% after reporting Q2 adjusted EPS of 79 cents, well above the consensus estimate of 54 cents, and raising its full-year adjusted EPS forecast to $3.35-$3.45, reflecting robust demand driven by AI.
- Labor Market Strength: US April JOLTS job openings unexpectedly rose by 731,000 to a 23-month high of 7.618 million, surpassing expectations of a decline to 6.866 million, indicating resilience in the labor market and further propelling stock market gains.
See More
US Stocks Rise Slightly, Tech Stocks Show Strong Rebound
- Strong Labor Market: US April JOLTS job openings unexpectedly rose by 731,000 to a 23-month high of 7.618 million, surpassing expectations of 6.866 million, indicating labor market resilience and driving stock market gains, particularly in tech stocks.
- Tech Stock Surge: Hewlett-Packard Enterprise (HPE) shares surged over 25% after reporting Q2 adjusted EPS of 79 cents, significantly above the consensus estimate of 54 cents, and raising its full-year adjusted EPS forecast to $3.35-$3.45, reflecting robust growth in AI-driven demand.
- Market Volatility Factors: Despite overall market gains, initial declines occurred due to uncertainty surrounding a US-Iran ceasefire, with oil prices slightly down as President Trump stated negotiations with Iran are progressing “at a rapid pace,” potentially affecting investor sentiment.
- Software Stocks Under Pressure: Intuit (INTU) saw its stock drop over 10% after Goldman Sachs downgraded it to sell with a price target of $276, leading to a broader decline in the software sector, highlighting a divergence in market performance among tech stocks.
See More
US Stocks Dip Slightly Amid Tech Sector Pressure
- Market Weakness: The S&P 500 index fell by 0.20%, the Dow Jones by 0.23%, and the Nasdaq 100 by 0.33%, indicating investor uncertainty regarding the US-Iran ceasefire prospects, which may dampen market confidence.
- Tech Sector Volatility: Software stocks faced declines, with Intuit dropping over 8% following a downgrade from Goldman Sachs, while Hewlett-Packard Enterprise surged over 33% due to soaring AI demand, highlighting a divergence within the tech industry.
- Inflation Expectations Shift: Hawkish comments from Cleveland Fed President raised rate hike expectations, with the 10-year T-note yield dropping to 4.422%, reflecting growing investor concerns about persistent inflation.
- Overseas Market Dynamics: European markets showed mixed results, with Eurozone May CPI rising 3.2% year-on-year, exceeding expectations and indicating signs of economic recovery, while China's stock market rebounded, reflecting the complexities of the global economy.
See More
RBC Capital Markets Initiates Praxis Precision with Outperform Rating
- Positive Market Outlook: RBC Capital Markets has initiated coverage on Praxis Precision Markets with an outperform rating, citing a recent pullback as a good entry point, and they expect a transformative next six months with a price target of $449, representing a 66% upside from the June 17 close.
- Significant Sales Potential: Analyst Leonid Timashev highlighted that ulixacaltamide has a sales potential exceeding $4.3 billion for essential tremor, acknowledging regulatory risks but noting strong physician willingness to prescribe, indicating a large unmet need in the market.
- Long-term Revenue Prospects: Timashev also mentioned that Praxis could achieve over $7.8 billion in revenue by 2035, which is attractive to investors and suggests strong growth potential in future market competition.
- New Drug Development Opportunities: For genetically driven epilepsy, Timashev sees a high probability of success for relutrigine, while elsunersen could contribute an additional $200 million for the most severe patients, although feedback indicates not all families would opt for this antisense oligonucleotide treatment.
See More
Latest Wall Street Rating Updates
- Apple Rating Reaffirmed: Bank of America reiterates Apple as a buy, believing that price increases are already reflected in the stock, anticipating that rising memory costs will force Apple to raise prices, impacting future earnings performance.
- Nice Upgrade: DA Davidson upgrades Nice from neutral to buy, maintaining a $110 price target, arguing that concerns about AI disruption are overblown, suggesting a more optimistic outlook that could boost the company's stock price.
- Immix Biopharma Initiation: Bank of America initiates coverage of Immix Biopharma with a buy rating and a $27 price target, citing the company's differentiated product offerings as a significant growth driver.
- Salesforce Upgrade: Monness Crespi Hardt upgrades Salesforce from neutral to buy with a $200 price target, based on its depressed valuation, strong cash flow generation, and support for customer transformation, which are expected to drive stock price increases.
See More
Wedbush Lowers Praxis Price Target to $162 After POWER1 Miss
- POWER1 Study Failure: Praxis Precision Medicines Inc.'s POWER1 study failed to meet its primary endpoint, prompting Wedbush to lower its 12-month price target from $355 to $162 while maintaining an Underperform rating, reflecting concerns over clinical development uncertainty.
- Need for Dose Adjustment: Although a more pronounced seizure reduction was observed at the 30mg dose, it still did not meet the prespecified endpoint, leading Praxis to pause enrollment in the POWER2 study to reassess potential modifications, indicating a cautious approach to future research directions.
- Positive Outlook for IDEAYA: Wedbush reaffirmed its Outperform rating on IDEAYA Biosciences with a price target of $58, based on positive results from the OptimUM-02 study, which demonstrated significant improvement in progression-free survival with Darovasertib plus Crizotinib compared to the control group.
- Strategic Deal for Edgewise: Edgewise Therapeutics reached a $1.55 billion agreement with Servier to sell all rights to Sevasemten, providing non-dilutive capital to strengthen its financial position and support a strategic focus on cardiac programs.
See More
US Stocks Close at All-Time Highs as AI Investments Surge
- Strong Market Performance: The S&P 500 rose by 0.13%, the Dow Jones by 0.45%, and the Nasdaq 100 by 0.48%, with all three indices reaching new all-time highs, reflecting strong investor confidence in tech stocks amid a surge in AI investments.
- Marvell Technology Soars: Marvell Technology's stock surged over 32% after Nvidia CEO Jensen Huang predicted the company would be the next to achieve a $1 trillion valuation, significantly boosting investor confidence in its future growth prospects.
- Hewlett Packard Enterprise's Strong Earnings: Hewlett Packard Enterprise's stock jumped more than 19% after reporting Q2 adjusted EPS of 79 cents, well above the consensus estimate of 54 cents, and raising its full-year adjusted EPS forecast to $3.35-$3.45, reflecting robust demand driven by AI.
- Labor Market Strength: US April JOLTS job openings unexpectedly rose by 731,000 to a 23-month high of 7.618 million, surpassing expectations of a decline to 6.866 million, indicating resilience in the labor market and further propelling stock market gains.
See More
US Stocks Rise Slightly, Tech Stocks Show Strong Rebound
- Strong Labor Market: US April JOLTS job openings unexpectedly rose by 731,000 to a 23-month high of 7.618 million, surpassing expectations of 6.866 million, indicating labor market resilience and driving stock market gains, particularly in tech stocks.
- Tech Stock Surge: Hewlett-Packard Enterprise (HPE) shares surged over 25% after reporting Q2 adjusted EPS of 79 cents, significantly above the consensus estimate of 54 cents, and raising its full-year adjusted EPS forecast to $3.35-$3.45, reflecting robust growth in AI-driven demand.
- Market Volatility Factors: Despite overall market gains, initial declines occurred due to uncertainty surrounding a US-Iran ceasefire, with oil prices slightly down as President Trump stated negotiations with Iran are progressing “at a rapid pace,” potentially affecting investor sentiment.
- Software Stocks Under Pressure: Intuit (INTU) saw its stock drop over 10% after Goldman Sachs downgraded it to sell with a price target of $276, leading to a broader decline in the software sector, highlighting a divergence in market performance among tech stocks.
See More
US Stocks Dip Slightly Amid Tech Sector Pressure
- Market Weakness: The S&P 500 index fell by 0.20%, the Dow Jones by 0.23%, and the Nasdaq 100 by 0.33%, indicating investor uncertainty regarding the US-Iran ceasefire prospects, which may dampen market confidence.
- Tech Sector Volatility: Software stocks faced declines, with Intuit dropping over 8% following a downgrade from Goldman Sachs, while Hewlett-Packard Enterprise surged over 33% due to soaring AI demand, highlighting a divergence within the tech industry.
- Inflation Expectations Shift: Hawkish comments from Cleveland Fed President raised rate hike expectations, with the 10-year T-note yield dropping to 4.422%, reflecting growing investor concerns about persistent inflation.
- Overseas Market Dynamics: European markets showed mixed results, with Eurozone May CPI rising 3.2% year-on-year, exceeding expectations and indicating signs of economic recovery, while China's stock market rebounded, reflecting the complexities of the global economy.
See More
